Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$73 Mln
P/E Ratio
--
P/B Ratio
9.67
Industry P/E
--
Debt to Equity
0.09
ROE
-20.28 %
ROCE
-1479.23 %
Div. Yield
0 %
Book Value
--
EPS
--
CFO
$-43.11 Mln
EBITDA
$-51.39 Mln
Net Profit
$-64.05 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Unicycive Therapeutics Inc (UNCY)
| -19.54 | -6.03 | 2.42 | -44.43 | -16.81 | -- | -- |
|
BSE Sensex
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Unicycive Therapeutics Inc (UNCY)
| -8.44 | 60.74 | -73.79 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.73 | 9,808.03 | 20.22 | 23.13 | |
| 284.42 | 8,956.09 | 22.08 | 58.42 | |
| 26.83 | 9,559.25 | -- | -28.77 | |
| 103.38 | 10,030.35 | 30.81 | 14.16 |
Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney... injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee's Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California. Address: 4300 El Camino Real, Los Altos, CA, United States, 94022 Read more
Founder, Chairman, CEO & President
Dr. Shalabh K. Gupta M.D., MPA
Founder, Chairman, CEO & President
Dr. Shalabh K. Gupta M.D., MPA
Headquarters
Los Altos, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Unicycive Therapeutics Inc (UNCY) stood at $ 32 Mln as on 31-Dec-24
The share price of Unicycive Therapeutics Inc (UNCY) is $0.64 (NASDAQ) as of 23-Apr-2025 14:41 EDT. Unicycive Therapeutics Inc (UNCY) has given a return of -16.81% in the last 3 years.
Unicycive Therapeutics Inc (UNCY) has a market capitalisation of $ 73 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Unicycive Therapeutics Inc (UNCY) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Unicycive Therapeutics Inc (UNCY) and enter the required number of quantities and click on buy to purchase the shares of Unicycive Therapeutics Inc (UNCY).
Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee's Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California. Address: 4300 El Camino Real, Los Altos, CA, United States, 94022
The CEO & director of Dr. Shalabh K. Gupta M.D., MPA. is Unicycive Therapeutics Inc (UNCY), and CFO & Sr. VP is Dr. Shalabh K. Gupta M.D., MPA.
There is no promoter pledging in Unicycive Therapeutics Inc (UNCY).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Unicycive Therapeutics Inc (UNCY) | Ratios |
|---|---|
|
Return on equity(%)
|
-2088.57
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Unicycive Therapeutics Inc (UNCY) was $0 Mln.
$0.02
(
